During the latest quarter, Prism Medico’s earnings per share (EPS) registered at Rs -0.13, while profit before depreciation, interest, and taxes (PBDIT) stood at Rs -0.10 crore. Operating cash flow for the year also showed a low of Rs -0.02 crore, signalling challenges in cash generation. These figures contrast with the company’s PAT of Rs 0.58 crore over the preceding six months, indicating some resilience in bottom-line metrics despite operational headwinds.
Patience pays off here! This Micro Cap from Fertilizers sector has delivered steady gains quarter after quarter. Now proudly part of our Reliable Performers list.
- New Reliable Performer
- Steady quarterly gains
- Fertilizers consistency
Market performance for Prism Medico & Pharmacy has been mixed relative to the broader Sensex index. Over the past week, the stock declined by 1.55%, while Sensex gained 0.96%. The one-month return for the stock was -5.80%, contrasting with Sensex’s 0.86% rise. Year-to-date figures show the stock down by 18.84%, whereas Sensex recorded an 8.36% increase. Over a one-year horizon, Prism Medico’s return was -24.32%, compared to Sensex’s 9.48%. Longer-term returns over three years show a positive 84.07% for the stock, outperforming Sensex’s 37.31%, though five-year and ten-year returns reveal underperformance relative to the benchmark.
Price movements on 19 Nov 2025 saw Prism Medico & Pharmacy’s stock open near Rs 18.95, with a day’s high of Rs 19.79 and a low of Rs 18.10, closing at Rs 19.64. The stock’s 52-week range spans from Rs 11.62 to Rs 26.85, indicating significant volatility within the past year. The market capitalisation grade remains modest at 4, reflecting its micro-cap status within the NBFC sector.
Holding Prism Medico & Pharmacy from Non Banking Financial Company (NBFC)? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- Peer comparison ready
- Superior options identified
- Cross market-cap analysis
Prism Medico’s recent adjustment in its financial trend parameter from positive to flat signals a period of consolidation for the company. The latest quarterly data points to operational challenges, particularly in cash flow and profitability metrics, which may influence investor sentiment. However, the company’s ability to maintain a positive PAT over six months suggests some underlying stability amid sector pressures.
Investors analysing Prism Medico & Pharmacy should consider the broader NBFC sector dynamics, where liquidity and credit quality remain key concerns. The stock’s historical returns over three years indicate potential for growth, but recent quarters highlight the need for cautious evaluation. Market participants may find value in monitoring further quarterly disclosures and sector developments to gauge the company’s trajectory.
Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
